Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CICLOPIROX vs AMPHOTERICIN B
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Topical treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis,Treatment of seborrheic dermatitis of the scalp,Treatment of cutaneous candidiasis (moniliasis) due to Candida albicans,Treatment of onychomycosis of fingernails and toenails due to Trichophyton rubrum,Off-label: Treatment of tinea versicolor, vaginal candidiasis, and superficial dermatophyte infections
Aspergillosis,Blastomycosis,Candidiasis,Coccidioidomycosis,Cryptococcosis,Histoplasmosis,Mucormycosis,Sporotrichosis,Visceral leishmaniasis,Empiric therapy for febrile neutropenia,Meningitis (cryptococcal, coccidioidal)
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Minimal systemic absorption following topical application. The small absorbed fraction is primarily metabolized via glucuronidation and oxidation. Unchanged drug and metabolites are excreted renally and fecally. Specific hepatic enzymes involved are not well characterized.
Primarily hepatic; exact enzymes not well characterized.
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
94-98% bound to plasma proteins, primarily albumin
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
1.2-2.0 L/kg, indicating extensive tissue distribution
4–5 L/kg (extensive tissue binding, especially in liver, spleen, and lungs).
Topical: minimal systemic absorption (<1-5% of applied dose); oral: not formulated for systemic use
IV: 100%; oral: <5%; topical: minimal systemic absorption.
No specific dose adjustments are recommended; systemic absorption is minimal (<1.3%) with topical application. For oral use (not available in the US), no data for renal impairment.
Acute kidney injury: consider dose reduction or switch to liposomal formulation. No specific GFR-based dose adjustments for conventional formulation; monitor renal function and electrolytes. For liposomal amphotericin B, no dosage adjustment required for renal impairment. Continuous renal replacement therapy: conventional amphotericin not recommended due to nephrotoxicity; liposomal preferred.
No dose adjustments needed for topical use due to negligible systemic absorption. No data for oral formulations.
No specific Child-Pugh based dose adjustments. Use caution in hepatic impairment; monitor liver function tests. Dose adjustment not typically required.
Ciclopirox 1% cream: Approved for children ≥10 years with tinea pedis or tinea corporis; apply twice daily for 2 weeks. Ciclopirox 8% nail lacquer: Not recommended in children <12 years. Ciclopirox 1% shampoo: Not established in children <16 years.
Conventional amphotericin B: 0.25-1.5 mg/kg/day IV; initial test dose 0.1 mg/kg. Liposomal amphotericin B: 3-5 mg/kg/day IV. For neonates: 1 mg/kg/day. Maximum daily dose: 1.5 mg/kg for conventional, 5 mg/kg for liposomal.
No specific dose adjustments; topical use has minimal systemic absorption. Consider skin thinning and increased risk of irritation in elderly; use caution with prolonged application.
Use with caution due to age-related renal function decline; monitor renal function and electrolyte levels carefully. Same dosing as adults; adjust for renal impairment if present. Lower doses may be considered based on clinical status.
None currently listed in FDA labeling.
Amphotericin B should be used primarily for progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of fungal disease. It should be used under close medical supervision due to potential toxicity.
For external use only; avoid contact with eyes and mucous membranes,If irritation or sensitivity develops, discontinue treatment,Not for intravaginal or ophthalmic use,Use in diabetic patients may require additional monitoring for nail infections,Keep away from heat and open flame (ciclopirox solution contains alcohol)
Monitor renal function, electrolytes, and liver function; risk of nephrotoxicity, hypokalemia, hypomagnesemia, and infusion-related reactions; caution in patients with renal impairment and those receiving other nephrotoxic drugs.
Hypersensitivity to ciclopirox or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation; unless the potential benefit outweighs the risk.
No significant food interactions have been reported with topical ciclopirox. For oral ciclopirox (not available in the US), food may affect absorption; consult prescribing information.
Avoid excessive salt intake; monitor for hypokalemia and hypomagnesemia. No specific food restrictions but maintain adequate hydration.
Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity in rats or rabbits. For topical use, there is no evidence of teratogenicity in humans. However, sufficient data are lacking for first trimester risk. The drug should be used during pregnancy only if clearly needed, with caution primarily in first trimester.
FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data suggest no increased risk of major malformations across all trimesters.
It is unknown if ciclopirox is excreted in human milk. Due to low systemic absorption after topical application, the amount ingested by a nursing infant is likely negligible. Use with caution on small areas and avoid application to breast. M/P ratio not established.
Excreted in breast milk in low levels; M/P ratio not established. Consideration of benefits vs risks; caution in nursing infants due to potential for oral absorption and adverse effects.
No pharmacokinetic changes requiring dose adjustment have been reported for topical ciclopirox. Systemic absorption is minimal and pregnancy-induced changes in skin permeability or clearance are not expected to alter systemic exposure significantly. Standard topical dosing (apply twice daily to affected areas) is appropriate.
No specific dose adjustments recommended in pregnancy; standard dosing based on indication and patient weight. Pharmacokinetic changes in pregnancy (increased Vd, increased clearance) may theoretically require higher doses, but clinical data insufficient to recommend adjustment.
Apply topical ciclopirox once or twice daily, covering the lesion and a 1 cm margin of normal skin. For nail infections, file away loose nail material before applying lacquer. Avoid occlusive dressings unless directed. Treatment duration for tinea pedis is 2 weeks; for tinea corporis/cruris, 2-4 weeks. For onychomycosis, treatment may require 48 weeks or until nail replacement.
Premedicate with acetaminophen, diphenhydramine, and hydrocortisone to reduce infusion-related reactions. Monitor serum potassium and magnesium closely due to renal wasting. Use normal saline bolus before infusion to reduce nephrotoxicity. Lipid formulations allow higher doses with less nephrotoxicity. Amphotericin B deoxycholate is reserved for severe, refractory cases.
Wash hands before and after applying the medication.,Apply a thin layer to the affected area and rub in gently.,Do not use on open wounds, or in eyes, mouth, or vagina.,For nail lacquer, apply daily over the entire nail plate and to the underside of the nail tip.,Avoid nail polish or artificial nails during treatment.,Complete the full course even if symptoms improve.,Notify your doctor if irritation or allergic reaction occurs.
You may experience fever, chills, and nausea during infusion; these are common and can be managed with premedications.,Report any signs of kidney problems such as decreased urine output, swelling in legs, or fatigue.,Avoid potassium and magnesium supplements unless prescribed, as levels may fluctuate.,This medication can cause low blood pressure during infusion; rise slowly from sitting or lying down.,Complete the full course even if you feel better to prevent the infection from returning.
"Combining ciclopirox, an antifungal agent, with benidipine, a calcium channel blocker, may result in increased toxicity or reduced therapeutic efficacy. Benidipine is metabolized via CYP3A4; ciclopirox can inhibit CYP3A4, potentially raising benidipine plasma concentrations and causing hypotension, dizziness, or peripheral edema. Additionally, ciclopirox may have additive cardiodepressant effects, leading to bradycardia or worsening heart failure in susceptible patients."
"Co-administration of Ciclopirox and Eperisone may lead to additive antagonism of normal muscle tone and coordination due to concurrent central nervous system depression. Ciclopirox, primarily used for dermatological conditions, has noted sedative effects from systemic absorption, while Eperisone centrally acts as a muscle relaxant with sedative properties. The combined use can potentiate drowsiness, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents."
"Losartan, an angiotensin II receptor blocker, and ciclopirox, a topical antifungal, are not expected to have a clinically significant pharmacokinetic interaction. Ciclopirox is minimally absorbed through the skin (<0.01% of applied dose) and undergoes hepatic glucuronidation and renal excretion. Losartan is metabolized primarily by CYP2C9 and CYP3A4 to its active metabolite. The baseline statement suggests a theoretical inhibition of ciclopirox metabolism by losartan, but given ciclopirox's negligible systemic exposure after topical use and different metabolic pathways, this interaction is unlikely to produce adverse clinical outcomes."
"Efinaconazole, a triazole antifungal, inhibits fungal CYP450-dependent lanosterol 14α-demethylase, reducing ergosterol synthesis. Amphotericin B binds to ergosterol in fungal membranes, forming pores that cause cell death. Concomitant use may decrease Amphotericin B efficacy because efinaconazole depletes ergosterol, the target for Amphotericin B, potentially attenuating the polyene's antifungal activity, especially in systemic fungal infections."
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CICLOPIROX vs AMPHOTERICIN B, answered by our medical review team.
CICLOPIROX is a Antifungal that works by Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.. AMPHOTERICIN B is a Antifungal that works by Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CICLOPIROX and AMPHOTERICIN B depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CICLOPIROX is: Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).. The standard adult dose of AMPHOTERICIN B is: 0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CICLOPIROX and AMPHOTERICIN B. The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Ciclopirox. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CICLOPIROX is classified as Category A/B. Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity i. AMPHOTERICIN B is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data sug. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.